Seeking Alpha

The FDA finds that a heart stent developed by Stryker (SYK) might not be worth the additional...

The FDA finds that a heart stent developed by Stryker (SYK) might not be worth the additional risks for patients because it offers no added benefits over existing drugs used to help prevent strokes. (report)
Comments (1)
  • Koshien Kid
    , contributor
    Comments (184) | Send Message
     
    The FDA's job is to determine whether or not a device or a compound is safe for patients. Its job is most emphatically NOT to assess the cost-benefit relationship for a particular treatment; that is up to the patient and his or her physician, subject to whatever constraints are imposed by the patient's ability to fund the treatment.
    This smells like a very sneaky effort on the part of the current administration to squeeze rationing into their PPACA scheme.
    21 Mar 2012, 09:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector